Literature DB >> 7768646

Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages.

T Daemen1, G Hofstede, M T Ten Kate, I A Bakker-Woudenberg, G L Scherphof.   

Abstract

Doxorubicin entrapped within conventional liposomes (200 nm in diameter; lip-Dox) has major toxic effects on liver macrophages of the rat for a considerable period of time following i.v. administration, with respect to both specific phagocytic capacity and cell numbers. At different time-points after injection of lip-Dox or free doxorubicin, radiolabeled, negatively charged, "empty" test liposomes were injected. Phagocytic capacity was determined by isolating the liver macrophages and measuring the amount of macrophage-associated radioactivity. Four subfractions of liver macrophages of different cell-size and with intrinsically different phagocytic capacity were isolated. Twenty-four hours after injection of lip-Dox, the phagocytic capacity of the larger-sized liver macrophages was strongly decreased. The relatively low intrinsic phagocytic capacity of the smaller-sized macrophages was only slightly impaired. Phagocytic capacity after injection of lip-Dox was nearly restored to control values after 14 days. Blood clearance of Klebsiella pneumoniae bacteria after pre-treatment with lip-Dox was strongly decreased. Pre-treatment with the free drug and/or placebo liposomes had no effect on phagocytic and bacterial blood-clearance capacity. A major depletion of the liver macrophage population was observed, as revealed by both macrophage isolation and histology. Only 2 weeks after injection of lip-Dox, the number of cells had returned to that seen in control animals. In view of the important host-defense functions of the liver macrophages, especially in the control of tumor growth and infection, the findings reported here should be taken into consideration when lip-Dox is to be administered in anti-tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768646     DOI: 10.1002/ijc.2910610520

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles.

Authors:  Aaron F H Lum; Mark A Borden; Paul A Dayton; Dustin E Kruse; Scott I Simon; Katherine W Ferrara
Journal:  J Control Release       Date:  2005-12-27       Impact factor: 9.776

2.  Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.

Authors:  E W van Etten; M T ten Kate; S V Snijders; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 3.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

Review 4.  A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Authors:  D N Waterhouse; P G Tardi; L D Mayer; M B Bally
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels.

Authors:  Dawn N Waterhouse; Tetyana Denyssevych; Norma Hudon; Stephen Chia; Karen A Gelmon; Marcel B Bally
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

Review 6.  Nanoparticles applied to cancer immunoregulation.

Authors:  Fernando Lopez-Campos; Danielle Candini; Eliseo Carrasco; Miguel Angel Berenguer Francés
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-02

7.  Liposome: classification, preparation, and applications.

Authors:  Abolfazl Akbarzadeh; Rogaie Rezaei-Sadabady; Soodabeh Davaran; Sang Woo Joo; Nosratollah Zarghami; Younes Hanifehpour; Mohammad Samiei; Mohammad Kouhi; Kazem Nejati-Koshki
Journal:  Nanoscale Res Lett       Date:  2013-02-22       Impact factor: 4.703

8.  Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  J Drug Deliv       Date:  2013-03-07

9.  Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil.

Authors:  Manuela Banciu; Raymond M Schiffelers; Gert Storm
Journal:  Pharm Res       Date:  2008-06-04       Impact factor: 4.200

Review 10.  Tumor targeting using liposomal antineoplastic drugs.

Authors:  Jörg Huwyler; Jürgen Drewe; Stephan Krähenbuhl
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.